Genelux Corporation


Genelux Corporation is a privately held, biopharmaceutical clinical stage company that was founded in 2001. The main focus of Genelux is oncolytic immunotherapy based on attenuated, genetically engineered oncolytic viruses as therapeutic agent.
In 2013 Genelux obtained the San Diego Business Journal Innovation Award in the category of Medical Research.

Locations

Genelux Corp. is headquartered in San Diego, California, with a business office in Redlands, California.

GL-ONC1

Genelux’s lead oncology compound is GL-ONC1, an oncolytic vaccinia virus. In November 2013 GL-ONC1 has been selected as one of the "Top 10 Oncology Projects to Watch" by Elsevier Business Intelligence. Currently, GL-ONC1 is being evaluated in human clinical Phase I/II studies, including an ongoing Phase II trial in recurrent ovarian cancer. In those studies GL-ONC1 was shown to be well tolerated and evidence of tumor colonization and indications for therapeutic efficacy were observed.

Veterinary lead compound

In addition to GL-ONC1, Genelux sponsors a veterinary trial in dogs with cancer that is conducted at the CVS Angel Care Cancer Center in Carlsbad, California. The dogs are treated with V-VET1, a non-genetically modified vaccinia virus isolate with an inactive thymidine kinase gene.

Pipeline

The preclinical pipeline of Genelux includes numerous genetically modified vaccinia virus strains with transgenes encoding for reporter proteins for deep tissue imaging, angiogenesis modifying proteins, radiosensitzing proteins, prodrug converting enzymes, biomarkers and immunomodulatory proteins.